since 2008, evaxion biotech has been pioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence, with the mission to solve some of the world’s most significant challenges to human health. evaxion has constructed a robust product engine for the development of novel vaccines and therapies based on our two platforms, pioneer and eden. using state of the art in silico tools, the platforms integrate big data, artificial intelligence and supercomputing to predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancers and infectious diseases. eden enables rapid and accurate discovery of novel antigens that elicit a highly cross-protective immune response in any bacterial pathogen while pioneer has been constructed to identify the epitopes of mutated proteins that will fire up the body’s natural immune responses to them. to learn more about evaxion, please visit http://www.evaxion-biotech.ai
Company profile
Ticker
EVAX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
EVAX stock data
Latest filings (excl ownership)
6-K
Evaxion Announces Business Update and Full Year 2023 Financial Results
27 Mar 24
20-F
2023 FY
Annual report (foreign)
26 Mar 24
6-K
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
19 Mar 24
6-K
Current report (foreign)
13 Mar 24
6-K
Current report (foreign)
29 Feb 24
6-K
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD
20 Feb 24
6-K
Current report (foreign)
7 Feb 24
6-K
Current report (foreign)
7 Feb 24
6-K
Evaxion Announces Closing of $15 Million Public Offering
6 Feb 24
424B4
Prospectus supplement with pricing info
5 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2023
3.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 106.70 mm |
Total shares | 122.71 k |
Total puts | 0.00 |
Total calls | 11.00 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
AE Wealth Management | 48.63 k | $40.51 mm |
Susquehanna International | 32.77 k | $28.19 mm |
Two Sigma Securities | 15.19 k | $12.65 mm |
JPM JPMorgan Chase & Co. | 9.28 k | $7.98 mm |
Beacon Capital Management | 6.88 k | $9.01 mm |
UBS UBS Group AG - Registered Shares | 4.01 k | $3.34 mm |
MS Morgan Stanley | 3.45 k | $2.87 mm |
Rhumbline Advisers | 2.11 k | $1.81 mm |
Group One Trading | 386.00 | $332.00 k |
Proequities | 0.00 | $0.00 |
News
Recap: Evaxion Biotech Q4 Earnings
27 Mar 24
Evaxion Biotech Q4 EPS $(0.16) Beats $(1.60) Estimate, Sales $73.00K
27 Mar 24
HC Wainwright & Co. Initiates Coverage On Evaxion Biotech with Buy Rating, Announces Price Target of $14
12 Feb 24
Evaxion Regains Compliance With Nasdaq Minimum Bid Price Requirement
7 Feb 24
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
1 Feb 24
Press releases
Evaxion Announces Business Update and Full Year 2023 Financial Results
27 Mar 24
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
19 Mar 24
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
29 Feb 24
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement
7 Feb 24
Evaxion Biotech Announces Pricing of $15 Million Public Offering
1 Feb 24